QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Trulieve Cannabis Corp. (TRLV)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
3

Bullish pullback-to-support limit: buy TRLV at 10.70 on the repeatedly tested 10.56–10.71 shelf, protective stop 10.01 (Change-A 1.0×ATR floor beneath the 10.56 swing low), targets 12.08 (2.0×ATR) and 13.12 (3.5×ATR), R/R 2.00 — all Step-00 gates passed (no earnings or dividend in the 15-day window, liquidity $15.0M/day, max overnight gap 1.8%, ATR 6.3% of price).

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

Trulieve Cannabis Corp. cultivates, processes, manufactures, and retails medical and adult-use cannabis products. The company operates its own cultivation and production facilities, distributing products through branded stores and home delivery. Headquartered in Tallahassee, FL, it was founded by Kim Rivers and Jason Pernell.

Fundamental

fair
Fundamental3
Mixed fundamentals

Trulieve's fundamentals show cash generation but are offset by revenue contraction and a significant tax contingency.

Mixed: the business throws off roughly $392M of Adjusted EBITDA and about $172M of free cash flow on a lightly levered balance sheet with $327M of cash, but revenue is contracting double digits, GAAP results remain negative, and a $625M Section 280E tax contingency with the IRS keeps the risk profile elevated.

Sentiment

fair
Sentiment3
Forming sentiment

Sentiment is forming, with trailing catalysts and no forward-dated drivers impacting the outlook.

Q3 2026 results (announced 2026-11-05; adjusted EPS $0.09 vs $0.04 consensus, 64% gross margin, $89M adjusted EBITDA, positive net income) and the DEA's final registrations for state-licensed medical marijuana (announced 2026-11-02, +0.60 item) are the dominant catalysts, both scored constructively, but they are trailing and only partially priced with no forward-dated event on the calendar. The 14-day media window is uniformly positive (+0.49 aggregate on 4 scored items) while the sentiment delta is indeterminate, because the 30–90 day baseline produced only two scorable items; the Red-Flag Screen is clean with no severe or moderate cap applied, so the mixed read reflects trailing, partially-priced catalysts and an unmeasured delta and retail read rather than a flagged risk.

Technical

fair
Technical3
Range-bound

Trulieve's stock is range-bound, with a potential entry at the 10.70 support level.

Mixed-but-tradable 3: the long-term frame is intact (price 10.90 sits 21.5% above a rising SMA200 at 8.97) and momentum is constructive (MACD line 0.08 above signal 0.05 and above zero, histogram +0.02), but the short-term stack is bearish (price below SMA20 10.92, EMA9 11.07, EMA21 10.99 and SMA50 11.14), RSI14 49.2 and Williams %R -53.5 are mid-range, and ADX14 at 14.3 (falling from 20.6) marks a range rather than a trend. The edge is a bid at the repeatedly tested 10.56–10.71 support shelf, not a trend continuation or a breakout chase.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.